新型冠状病毒检测与治疗 |
|
|
|
|
CRISPR/Cas9在人病毒感染相关疾病治疗研究中的应用* |
王伟东,杜加茹,张运尚,樊剑鸣() |
郑州大学公共卫生学院 郑州 450001 |
|
The Application of CRISPR/Cas9 in the Treatment of Human Virus Infection-Related Diseases |
WANG Wei-dong,DU Jia-ru,ZHANG Yun-shang,FAN Jian-ming() |
School of Public Health, Zhengzhou University,Zhengzhou 450001, China |
引用本文:
王伟东,杜加茹,张运尚,樊剑鸣. CRISPR/Cas9在人病毒感染相关疾病治疗研究中的应用*[J]. 中国生物工程杂志, 2020, 40(12): 18-24.
WANG Wei-dong,DU Jia-ru,ZHANG Yun-shang,FAN Jian-ming. The Application of CRISPR/Cas9 in the Treatment of Human Virus Infection-Related Diseases. China Biotechnology, 2020, 40(12): 18-24.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2009025
或
https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I12/18
|
[1] |
Mahfouz M M, Li L, Shamimuzzaman M, et al. De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks. Proc Natl Acad Sci USA, 2011,108(6):2623-2628.
pmid: 21262818
|
[2] |
Doudna J A, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science, 2014,346(6213):1258096.
doi: 10.1126/science.1258096
pmid: 25430774
|
[3] |
Jansen R, Embden J D, Gaastra W, et al. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol, 2002,43(6):1565-1575.
doi: 10.1046/j.1365-2958.2002.02839.x
pmid: 11952905
|
[4] |
Grissa I, Vergnaud G, Pourcel C. The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats. BMC Bioinformatics, 2007,8(1):172.
|
[5] |
Horvath P, Romero D A, Coûté-Monvoisin A C, et al. Diversity, activity, and evolution of CRISPR loci in Streptococcus thermophilus. Journal of Bacteriology, 2008,190(4):1401-1412.
doi: 10.1128/JB.01415-07
pmid: 18065539
|
[6] |
Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012,337(6096):816-821.
pmid: 22745249
|
[7] |
Makarova K S, Aravind L, Grishin N V, et al. A DNA repair system specific for thermophilic Archaea and bacteria predicted by genomic context analysis. Nucleic Acids Research, 2002,30(2):482-496.
pmid: 11788711
|
[8] |
Makarova K S, Haft D H, Barrangou R, et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol, 2011,9(6):467-477.
pmid: 21552286
|
[9] |
Garneau J E, Dupuis M è, Villion M, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature, 2010,468(7320):67-71.
pmid: 21048762
|
[10] |
Deltcheva E, Chylinski K, Sharma C M, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature, 2011,471(7340):602-607.
pmid: 21455174
|
[11] |
Maartens G, Celum C, Lewin S R. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet, 2014,384(9939):258-271.
doi: 10.1016/S0140-6736(14)60164-1
pmid: 24907868
|
[12] |
Ebina H, Misawa N, Kanemura Y, et al. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Scientific Reports, 2013,3(1):7.
|
[13] |
Chan D C, Kim P S. HIV entry and its inhibition. Cell, 1998,93(5):681-684.
doi: 10.1016/s0092-8674(00)81430-0
pmid: 9630213
|
[14] |
Li C, Guan X M, Du T, et al. Inhibition of HIV-1 infection of primary CD4(+) T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. Journal of General Virology, 2015,96(Pt-8):2381-2393.
|
[15] |
Xu L, Yang H, Gao Y, et al. CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo. Molecular Therapy, 2017,25(8):1782-1789.
doi: 10.1016/j.ymthe.2017.04.027
pmid: 28527722
|
[16] |
Xiao Q Q, Chen S L, Wang Q K, et al. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4(+) T cells and hematopoietic stem/progenitor cells promotes HIV-1 resistance and CD4(+) T cell enrichment in humanized mice. Retrovirology, 2019,16:17.
doi: 10.1186/s12977-019-0479-9
pmid: 31242909
|
[17] |
Connor R I, Sheridan K E, Ceradini D, et al. Change in coreceptor use correlates with disease progression in HIV-1: infected individuals. The Journal of experimental medicine, 1997,185(4):621-628.
doi: 10.1084/jem.185.4.621
pmid: 9034141
|
[18] |
Wang Q K, Chen S L, Xiao Q Q, et al. Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection. Retrovirology, 2017,14(1):12.
doi: 10.1186/s12977-017-0338-5
pmid: 28193275
|
[19] |
Hou P P, Chen S L, Wang S L, et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Scientific Reports, 2015,5(1):12.
|
[20] |
Liu Z P, Chen S L, Jin X, et al. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4(+) T cells from HIV-1 infection. Cell and Bioscience, 2017,7(1):15.
doi: 10.1186/s13578-017-0142-x
|
[21] |
Trepo C, Chan H L Y, Lok A. Hepatitis B virus infection. Lancet, 2014,384(9959):2053-2063.
doi: 10.1016/S0140-6736(14)60220-8
pmid: 24954675
|
[22] |
Maepa M B, Jacobs R, Van Den Berg F, et al. Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus. Current Opinion in Hiv and Aids, 2020,15(3):200-207.
doi: 10.1097/COH.0000000000000623
pmid: 32141890
|
[23] |
Ramanan V, Shlomai A, Cox D B T, et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Scientific Reports, 2015,5(1):10833.
|
[24] |
Wang J, Xu Z W, Liu S, et al. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World Journal of Gastroenterology, 2015,21(32):9554-9565.
doi: 10.3748/wjg.v21.i32.9554
pmid: 26327763
|
[25] |
Li H, Sheng C Y, Wang S, et al. Removal of integrated hepatitis B virus DNA using CRISPR-Cas9. Frontiers in Cellular and Infection Microbiology, 2017,7:91.
doi: 10.3389/fcimb.2017.00091
pmid: 28382278
|
[26] |
Liu Y, Zhao M X, Gong M X, et al. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus. Antiviral Research, 2018,152:58-67.
doi: 10.1016/j.antiviral.2018.02.011
pmid: 29458131
|
[27] |
Song J, Zhang X C, Ge Q Y, et al. CRISPR/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells. Journal of Cellular Biochemistry, 2018,119(10):8419-8431.
pmid: 29904948
|
[28] |
Zhou S J, Deng Y L, Liang H F, et al. Hepatitis B virus X protein promotes CREB-mediated activation of miR-3188 and Notch signaling in hepatocellular carcinoma. Cell Death and Differentiation, 2017,24(9):1577-1587.
doi: 10.1038/cdd.2017.87
pmid: 28574502
|
[29] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018,68(6):394-424.
doi: 10.3322/caac.21492
pmid: 30207593
|
[30] |
Yeo-Teh N S L, Ito Y, Jha S. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. Int J Mol Sci, 2018,19(6):1706.
doi: 10.3390/ijms19061706
|
[31] |
Zhen S, Hua L, Takahashi Y, et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochemical and Biophysical Research Communications, 2014,450(4):1422-1426.
doi: 10.1016/j.bbrc.2014.07.014
|
[32] |
Zhen S, Lu J J, Wang L J, et al. In vitro and in vivo synergistic therapeutic effect of cisplatin with human papillomavirus16 E6/E7 CRISPR/Cas9 on cervical cancer cell line. Translational Oncology, 2016,9(6):498-504.
doi: 10.1016/j.tranon.2016.10.002
pmid: 27816686
|
[33] |
Pirouzfar M, Amiri F, Dianatpour M, et al. CRISPR/Cas9-mediated knockout of MLL5 enhances apoptotic effect of cisplatin in HeLa cells in vitro. Excli Journal, 2020,19:170-182.
doi: 10.17179/excli2019-1957
pmid: 32194363
|
[34] |
Zhong S, Zhang Y, Yin X, et al. CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer. Oncotargets and Therapy, 2019,12:2137-2147.
doi: 10.2147/OTT
|
[35] |
Ling K, Yang L, Yang N, et al. Gene targeting of HPV18 E6 and E7 synchronously by nonviral transfection of CRISPR/Cas9 system in cervical cancer. Human Gene Therapy, 2020,31(5-6):297-308.
doi: 10.1089/hum.2019.246
pmid: 31989837
|
[36] |
Van Diemen F R, Kruse E M, Hooykaas M J G, et al. CRISPR/Cas9-mediated genome editing of herpesviruses limits productive and latent infections. Plos Pathogens, 2016,12(6):29.
|
[37] |
Turner E M, Brown R S H, Laudermilch E, et al. The Torsin activator LULL1 is required for efficient growth of herpes simplex virus 1. Journal of Virology, 2015,89(16):8444-8452.
doi: 10.1128/JVI.01143-15
pmid: 26041288
|
[38] |
Roehm P C, Shekarabi M, Wollebo H S, et al. Inhibition of HSV-1 replication by gene editing strategy. Scientific Reports, 2016,6(5457):23146.
|
[39] |
Latif M B, Raja R, Kessler P M, et al. Relative contributions of the cGAS-STING and TLR3 signaling pathways to attenuation of herpes simplex virus 1 replication. Journal of Virology, 2020,94(6):e01717-19.
doi: 10.1128/JVI.01717-19
pmid: 31896590
|
[40] |
Young L S, Rickinson A B. Epstein-Barr virus: 40 years on. Nat Rev Cancer, 2004,4(10):757-768.
doi: 10.1038/nrc1452
pmid: 15510157
|
[41] |
Su S, Zou Z, Chen F, et al. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology, 2017,6(1):e1249558.
doi: 10.1080/2162402X.2016.1249558
pmid: 28197365
|
[42] |
Yuen K S, Wang Z M, Wong N H M, et al. Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR/Cas9. Virus Research, 2018,244:296-303.
doi: 10.1016/j.virusres.2017.04.019
pmid: 28456574
|
[43] |
Huo H, Hu G. CRISPR/Cas9-mediated LMP1 knockout inhibits Epstein-Barr virus infection and nasopharyngeal carcinoma cell growth. Infectious Agents and Cancer, 2019,14(4):30.
doi: 10.1186/s13027-019-0246-5
|
[44] |
Janoly-Dumenil A, Rouvet I, Bleyzac N, et al. A pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection. Antimicrobial Agents and Chemotherapy, 2012,56(7):3732-3738.
doi: 10.1128/AAC.06423-11
pmid: 22526305
|
[45] |
King M W, Munger J. Editing the human cytomegalovirus genome with the CRISPR/Cas9 system. Virology, 2019,529:186-194.
doi: 10.1016/j.virol.2019.01.021
pmid: 30716580
|
[46] |
Gergen J, Coulon F, Creneguy A, et al. Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential viral gene. PLoS One, 2018,13(2):e0192602.
doi: 10.1371/journal.pone.0192602
pmid: 29447206
|
[47] |
Tai-Schmiedel J, Karniely S, Lau B, et al. Human cytomegalovirus long noncoding RNA4.9 regulates viral DNA replication. PLoS Pathogens, 2020,16(4):e1008390.
doi: 10.1371/journal.ppat.1008390
pmid: 32294138
|
[48] |
He M, Yuan H, Tan B, et al. SIRT1-mediated downregulation of p27(Kip1) is essential for overcoming contact inhibition of Kaposi’s sarcoma-associated herpesvirus transformed cells. Oncotarget, 2016,7(46):75698-75711.
doi: 10.18632/oncotarget.12359
pmid: 27708228
|
[49] |
Tso F Y, West J T, Wood C. Reduction of kaposi’s sarcoma-associated herpesvirus latency using CRISPR-Cas9 to edit the latency-associated nuclear antigen gene. Journal of Virology, 2019,93(7):e02183-18.
doi: 10.1128/JVI.02183-18
pmid: 30651362
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|